Click to download the PDF to view the full issue With the Zyprexa era over, Lilly is betting big on its ability to innovate in the pipeline. This past year […]
Click to download the PDF to view the full issue J&J emerged from a transitional 2012 continuing to generate annual sales increases and make significant advances on multiple fronts; the […]
Click to download the PDF to view the full issue The worst is not yet over for the pharma industry. Despite a general sense from many companies that the worst […]
Click to download the PDF to view the full issue Although the company’s long-time best seller Plavix fell off patent in 2012, a number of Bristol-Myers Squibb’s newer compounds – […]
Click to download the PDF to view the full issue With revenue of more than $20 billion, the largest generics portfolio globally, the world’s leading multiple sclerosis product, and a […]
Click to download the PDF to view the full issue Battered by the expiration of exclusivity of blockbuster products, Sanofi is driven to grow other areas of its business. The […]
Click to download the PDF to view the full issue Roche once again enjoyed growth in 2012 despite market difficulties, and the company continues its winning strategy of developing drugs […]
Click to download the PDF to view the full issue As Pfizer continues to be weighed down by Lipitor’s patent expiration, the company has sold off its animal health business […]
Click to download the PDF to view the full issue Med Ad News: What do you feel are the major strategic and marketplace challenges today for a company such as […]
Click to download the PDF to view the full issue For Novo Nordisk in 2012, laser-focused strategy paid off once again with double-digit growth, despite the continuing difficulties in the […]
